Overview of Advances in Recent Years for Patients With AML

Daniel A. Pollyea, MD, MS, assistant professor of Medicine at the University of Colorado Cancer Center and clinical director of Leukemia Services at the CU School of Medicine, discusses how far the field of acute myeloid leukemia (AML) has come in the last 1 to 2 years.

For years, this patient population had limited treatment options with poor outcomes, according to Pollyea. Over the last few years, there has been a huge acceleration in terms of options available for these patients.